Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590259 | 0.81 | ATR (0.43) | ATR | |
| SCHEMBL2684912 | 0.81 | CYP1A2 (0.59) | ALDH1A1MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL4384494 | 0.79 | MAPK1 (0.46) | ALDH1A1MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL164625 | 0.79 | MAPK1 (0.46) | ALDH1A1MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL31133102 | 0.79 | HCRTR1 (0.45) | ALDH1A1MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL2012751 | 0.79 | ALDH1A1 (0.45) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL1427770 | 0.78 | RAB9A (0.43) | NPC1RAB9ASMN1; SMN2MAPTIDH1 | |
| SCHEMBL15500861 | 0.78 | MAPT (0.46) | ALDH1A1MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL22518516 | 0.78 | MAPK1 (0.44) | ALDH1A1MAPK1CYP1A2NPC1RAB9A | |
| SCHEMBL1789196 | 0.78 | ROCK1 (0.55) | ALDH1A1MAPK1CYP1A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12612388-B2 | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | Sironax Ltd. (KY) | 2026-04-28 | — | — | US | disclosed |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121574100-A | Aminopyrimidine derivative and preparation method and application thereof | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2026-02-27 | — | — | CN | disclosed |
| EP-4676918-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | Nanjing Immunophage Biomedical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-12514858-B2 | CD38 inhibitors | Astellas Engineered Small Molecules US, Incorporated (US) | 2026-01-06 | — | — | US | disclosed |
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| CN-1882568-A | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| CN-1659131-A | (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LTD (GB) | 2005-08-24 | — | — | CN | disclosed |
| EP-1492757-A1 | (2-((2-ALKOXY)-PHENYL)-CYCLOPENT-1-ENYL) AROMATIC CARBO- AND HETEROCYCLIC CARBOXYLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084917-A1 | (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
| US-5591853-A | CHEMICAL INTERMEDIATE PRODUCTS FOR PHARMACEUTICALS | LONZA LTD. (CH) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509467-B2 | CGAS inhibiting triazolopyrimidone derivatives | CGAS, STING1, IRF3 | ALDH1A1 1347/4885MAPK1 1410/4885CYP1A2 718/4885 |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | ALDH1A1 586/4885MAPK1 3388/4885CYP1A2 11/4885 |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | ALDH1A1 2891/4885MAPK1 2179/4885CYP1A2 1032/4885 |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | ALDH1A1 2657/4885MAPK1 2994/4885CYP1A2 4455/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | ALDH1A1 632/4885MAPK1 2422/4885CYP1A2 124/4885 |
| US-12612388-B2 | Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas | NCOR1, NCOR2, SUCNR1 | ALDH1A1 4498/4885MAPK1 1171/4885CYP1A2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.